Valerion Therapeutics LLC

Valerion Therapeutics develops therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system.

Valerion Therapeutics, LLC (formerly 4s3 Bioscience) is developing therapies for orphan genetic muscle diseases utilizing a novel antibody-based targeting system capable of enhanced intracellular delivery. Demonstrated pre-clinical in vivo data with the company’s two lead product candidates validates the potential of the 4s3 delivery platform for delivering muscle-protein fusions and treating multiple indications in the fields of muscular dystrophies and enzyme-deficiency disorders.